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Background
Tumor necrosing factor antagonists are being widely used
for the treatment of juvenile idiopathic arthritis (JIA). One
concern during the treatment with anti-TNF agents is the
risk of activating tuberculosis (Tbc).
Aim
We evaluated JIA patients who received anti-TNF treat-
ment, from an eastern Mediterranean country with mod-
erate tuberculosis frequency (official notification rate is
27/100 000).
Materials and methods
Thirty-seven JIA patients under anti-TNF treatment were
enrolled to the study. Chest-X rays, purified protein deriv-
ative (PPD) tests, clinical histories and physical examina-
tions were reviewed retrospectively. If PPD was above 10
mm in a patient with one BCG vaccination, family screen-
ing, cultures and if needed thorax computerized tomogra-
phy were obtained and isoniazid prophylaxis was started
for a period of 9 months. All were re-evaluated within 3
month intervals.
Results
Fifteen were females, 22 were males. Mean age was 14.2 ±
5.3 years. Mean follow up after initiation of etanercept
was 12.7 ± 10.9 months. Seven patients had an initial PPD
score above 10 mm. All received concomitant isoniazid
treatment. Except one patient with a very severe course of
systemic JIA under aggressive immunosuppressive ther-
apy, all had normal examinations and X-rays. This one
patient had a consolidation and cavitation at his right
superioposterior lung zones. He is on antituberculosis
treatment now without any overt clinical features of Tbc.
Conclusion
With proper initial evaluation anti-TNF treatment is safe
even in countries where Tbc is moderate frequency. A 9-
month isoniasid treatment is suggested for children with
a ppd of >10 mm.
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